In 2021, the Center for Drug Evaluation of the National Medical Products Administration (NMPA) in China received more than 1,800 Investigational New Drug (IND) applications for innovative drugs. The application number grew substantially in the past few years, with the 2021 figure almost 80 percent higher than the previous year. Almost all IND applications were concerning innovative chemical drugs or biopharmaceuticals, with only 44 innovative Traditional Chinese Medicine (TCM) IND applications submitted in 2021.
An Investigational New Drug (IND) is a drug or biopharmaceutical product that is not yet approved for general use by the regulatory body while being used in clinical trials to examine its efficacy and safety. An IND application is the prerequisite for a drug product to enter its clinical trial phase.
Number of Investigational New Drug (IND) applications for innovative drugs submitted in China from 2018 to 2021, by drug type
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
National Medical Products Administration. (June 1, 2022). Number of Investigational New Drug (IND) applications for innovative drugs submitted in China from 2018 to 2021, by drug type [Graph]. In Statista. Retrieved December 23, 2024, from https://www.statista.com/statistics/1319951/china-number-of-investigationa-new-drug-applications-of-innovative-drugs-submitted/
National Medical Products Administration. "Number of Investigational New Drug (IND) applications for innovative drugs submitted in China from 2018 to 2021, by drug type." Chart. June 1, 2022. Statista. Accessed December 23, 2024. https://www.statista.com/statistics/1319951/china-number-of-investigationa-new-drug-applications-of-innovative-drugs-submitted/
National Medical Products Administration. (2022). Number of Investigational New Drug (IND) applications for innovative drugs submitted in China from 2018 to 2021, by drug type. Statista. Statista Inc.. Accessed: December 23, 2024. https://www.statista.com/statistics/1319951/china-number-of-investigationa-new-drug-applications-of-innovative-drugs-submitted/
National Medical Products Administration. "Number of Investigational New Drug (Ind) Applications for Innovative Drugs Submitted in China from 2018 to 2021, by Drug Type." Statista, Statista Inc., 1 Jun 2022, https://www.statista.com/statistics/1319951/china-number-of-investigationa-new-drug-applications-of-innovative-drugs-submitted/
National Medical Products Administration, Number of Investigational New Drug (IND) applications for innovative drugs submitted in China from 2018 to 2021, by drug type Statista, https://www.statista.com/statistics/1319951/china-number-of-investigationa-new-drug-applications-of-innovative-drugs-submitted/ (last visited December 23, 2024)
Number of Investigational New Drug (IND) applications for innovative drugs submitted in China from 2018 to 2021, by drug type [Graph], National Medical Products Administration, June 1, 2022. [Online]. Available: https://www.statista.com/statistics/1319951/china-number-of-investigationa-new-drug-applications-of-innovative-drugs-submitted/
